TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity-MedSci.cn

TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

Bagegni, NA; Grigsby, I; Nehring, L; Luo, JQ; Carson, JP; Gibson, DW; Horvath, M; Clifton, KK; Ademuyiwa, FO; Suresh, R; Frith, A; Davis, AA; Peterson, LL; Bose, R; Williams, A; Bergqvist, M; Ma, C

CANCER RESEARCH, 2023; 83 (5):

科室
- - 订阅+
  - 更多科室
工具
服务